Cullinan Therapeutics (NASDAQ: CGEM) shareholders back directors, KPMG and pay
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Cullinan Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 16, 2026. Stockholders elected two Class III directors to three-year terms. Nadim Ahmed received 37,519,241 votes for and 12,116,759 votes withheld, while Stephen Webster received 36,963,086 votes for and 12,672,914 votes withheld.
Stockholders also ratified KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2026, with 53,722,477 votes for, 36,815 against, and 3,138 abstentions. In an advisory vote, stockholders approved compensation for the named executive officers, with 48,536,734 votes for, 1,092,209 against, 7,057 abstentions, and 4,126,430 broker non-votes.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Annual Meeting date: June 16, 2026
Votes for Nadim Ahmed: 37,519,241 votes
Votes for Stephen Webster: 36,963,086 votes
+4 more
7 metrics
Annual Meeting date
June 16, 2026
Date of Cullinan Therapeutics Annual Meeting of Stockholders
Votes for Nadim Ahmed
37,519,241 votes
Election as Class III director at 2026 Annual Meeting
Votes for Stephen Webster
36,963,086 votes
Election as Class III director at 2026 Annual Meeting
Votes for KPMG ratification
53,722,477 votes
Ratification as independent registered accounting firm for 2026
Votes against KPMG ratification
36,815 votes
Opposing ratification of KPMG for fiscal year 2026
Say-on-pay votes for
48,536,734 votes
Advisory approval of named executive officer compensation
Say-on-pay votes against
1,092,209 votes
Opposing advisory vote on executive compensation
Key Terms
Annual Meeting of Stockholders, broker non-votes, independent registered accounting firm, advisory vote on executive compensation, +1 more
5 terms
Annual Meeting of Stockholders regulatory
"The Annual Meeting of Stockholders (the “Annual Meeting”) of Cullinan Therapeutics, Inc."
broker non-votes regulatory
"Nadim Ahmed | 37,519,241 | 12,116,759 | 4,126,430"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered accounting firm regulatory
"ratified the appointment of KPMG LLP as the Company’s independent registered accounting firm"
advisory vote on executive compensation regulatory
"approved the advisory vote on the compensation of the Company’s named executive officers"
A non-binding shareholder vote allowing investors to approve or reject the pay packages and compensation policies for a company’s top executives. It matters because the outcome tells the board whether owners are satisfied with executive pay and can prompt changes in policy or leadership much like a customer survey prompts a company to adjust its product — signaled approval can support management credibility, while rejection may increase scrutiny and affect investor confidence.
Emerging growth company regulatory
"Emerging growth company Item 5.07 Submission of Matters to a Vote"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Cullinan Therapeutics (CGEM) stockholders vote on at the June 16, 2026 Annual Meeting?
Stockholders voted on electing two Class III directors, ratifying KPMG LLP as independent registered accounting firm for 2026, and approving an advisory vote on executive compensation. All three management proposals received the required support and were approved at the meeting.
Were Cullinan Therapeutics’ director nominees elected at the 2026 Annual Meeting?
Yes. Nadim Ahmed received 37,519,241 votes for and 12,116,759 withheld, and Stephen Webster received 36,963,086 votes for and 12,672,914 withheld, with 4,126,430 broker non-votes for each. Both Class III director nominees were elected to three-year terms on the Board.
Did Cullinan Therapeutics (CGEM) stockholders ratify KPMG as auditor for 2026?
Yes. Stockholders ratified KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2026, with 53,722,477 votes for, 36,815 against, and 3,138 abstentions. There were no broker non-votes recorded on this ratification proposal.
How did Cullinan Therapeutics stockholders vote on executive compensation in 2026?
Stockholders approved the advisory vote on compensation for named executive officers, with 48,536,734 votes for, 1,092,209 against, and 7,057 abstentions. There were 4,126,430 broker non-votes. This non-binding vote indicates support for the company’s current executive pay practices.
When was Cullinan Therapeutics’ 2026 Annual Meeting of Stockholders held?
The Annual Meeting of Stockholders was held on June 16, 2026. At this meeting, investors considered three proposals: election of two Class III directors, ratification of KPMG LLP as auditor for 2026, and an advisory vote on executive compensation, all of which were approved.